Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
Institute for Clinical and Experimental Medicine
Institute for Clinical and Experimental Medicine
Incyte Corporation
Emory University
Helse Møre og Romsdal HF
Janssen Scientific Affairs, LLC
Brigham and Women's Hospital
Hoffmann-La Roche
Hikma Pharmaceuticals LLC
University of Erlangen-Nürnberg Medical School
University of Campinas, Brazil
Alliance for Clinical Trials in Oncology
University of Leeds
FDA Office of Orphan Products Development
Medical University of Vienna
Centocor, Inc.
Emory University
Chinese University of Hong Kong